Inspira Technologies' Innovative Life-Support System to be Showcased at AmSECT 63rd International Conference 2025 in San Diego
Inspira Technologies (Nasdaq: IINN) announced the showcase of its FDA-cleared life-support system, the INSPIRA™ ART100, at the AmSECT 63rd International Conference in San Diego from March 19-23, 2025. The system, which received FDA 510(k) clearance in May 2024 for cardiopulmonary bypass procedures, will be displayed at distributor Glo-Med Networks' booth.
The conference, held at the Loews Coronado Bay Resort, provides a platform for leading perfusion professionals to experience Inspira's innovative extracorporeal circulation technology. The showcase represents an opportunity for the company to expand exposure of their technology within the perfusion community.
Inspira Technologies (Nasdaq: IINN) ha annunciato la presentazione del suo sistema di supporto vitale approvato dalla FDA, il INSPIRA™ ART100, alla 63ª Conferenza Internazionale AmSECT che si terrà a San Diego dal 19 al 23 marzo 2025. Il sistema, che ha ricevuto l'approvazione 510(k) della FDA nel maggio 2024 per le procedure di bypass cardiopolmonare, sarà esposto presso lo stand del distributore Glo-Med Networks.
La conferenza, che si svolgerà presso il Loews Coronado Bay Resort, offre una piattaforma per i principali professionisti della perfusione per conoscere la tecnologia innovativa di circolazione extracorporea di Inspira. Questa presentazione rappresenta un'opportunità per l'azienda di aumentare la visibilità della propria tecnologia all'interno della comunità di perfusione.
Inspira Technologies (Nasdaq: IINN) anunció la exhibición de su sistema de soporte vital autorizado por la FDA, el INSPIRA™ ART100, en la 63ª Conferencia Internacional AmSECT en San Diego del 19 al 23 de marzo de 2025. El sistema, que recibió la autorización 510(k) de la FDA en mayo de 2024 para procedimientos de bypass cardiopulmonar, se exhibirá en el stand del distribuidor Glo-Med Networks.
La conferencia, que se llevará a cabo en el Loews Coronado Bay Resort, proporciona una plataforma para que los principales profesionales de la perfusión experimenten la innovadora tecnología de circulación extracorpórea de Inspira. La exhibición representa una oportunidad para que la empresa amplíe la visibilidad de su tecnología dentro de la comunidad de perfusión.
Inspira Technologies (Nasdaq: IINN)는 2025년 3월 19일부터 23일까지 샌디에이고에서 열리는 제63회 AmSECT 국제 회의에서 FDA 승인을 받은 생명 유지 시스템인 INSPIRA™ ART100을 선보일 예정이라고 발표했습니다. 이 시스템은 2024년 5월에 심폐 우회 수술을 위한 FDA 510(k) 승인을 받았으며, 배급업체 Glo-Med Networks의 부스에서 전시될 것입니다.
Loews Coronado Bay Resort에서 열리는 이 회의는 주요 관류 전문가들이 Inspira의 혁신적인 체외 순환 기술을 경험할 수 있는 플랫폼을 제공합니다. 이 전시는 회사가 관류 커뮤니티 내에서 기술의 노출을 확대할 수 있는 기회를 나타냅니다.
Inspira Technologies (Nasdaq: IINN) a annoncé la présentation de son système de soutien vital approuvé par la FDA, le INSPIRA™ ART100, lors de la 63e Conférence Internationale AmSECT à San Diego du 19 au 23 mars 2025. Le système, qui a reçu l'approbation 510(k) de la FDA en mai 2024 pour les procédures de contournement cardiopulmonaire, sera exposé au stand du distributeur Glo-Med Networks.
La conférence, qui se tiendra au Loews Coronado Bay Resort, offre une plateforme aux principaux professionnels de la perfusion pour découvrir la technologie innovante de circulation extracorporelle d'Inspira. Cette présentation représente une opportunité pour l'entreprise d'accroître la visibilité de sa technologie au sein de la communauté de perfusion.
Inspira Technologies (Nasdaq: IINN) gab die Präsentation seines von der FDA genehmigten Lebenserhaltungssystems, dem INSPIRA™ ART100, auf der 63. Internationalen AmSECT-Konferenz in San Diego vom 19. bis 23. März 2025 bekannt. Das System, das im Mai 2024 die FDA 510(k)-Genehmigung für kardiopulmonale Bypass-Verfahren erhielt, wird am Stand des Distributors Glo-Med Networks ausgestellt.
Die Konferenz, die im Loews Coronado Bay Resort stattfindet, bietet eine Plattform für führende Perfusionsspezialisten, um die innovative extrakorporale Zirkulationstechnologie von Inspira kennenzulernen. Die Präsentation stellt eine Gelegenheit für das Unternehmen dar, die Sichtbarkeit seiner Technologie innerhalb der Perfusionsgemeinschaft zu erhöhen.
- FDA 510(k) clearance received for INSPIRA ART100 system in May 2024
- None.
Leading perfusion professionals to experience Inspira's FDA-cleared cardiopulmonary bypass INSPIRA™ ART100 technology at premier industry event
RA'ANANA,
Conference attendees will have the opportunity to explore Inspira's cutting-edge cardiopulmonary bypass technology at Glo-Med's booth. The INSPIRA ART100 system, which received FDA 510(k) clearance in May 2024 for use in cardiopulmonary bypass procedures, represents an advancement in extracorporeal circulation technology.
"The AmSECT International Conference brings together leading perfusion professionals, providing an ideal platform to showcase our INSPIRA ART100 system," said Dagi Ben-Noon, Chief Executive Officer of Inspira Technologies. "This event offers an excellent opportunity to further expose our innovative technology to the perfusion community. We look forward to connecting with industry experts and demonstrating how our solutions can support medical professionals."
Visitors interested in scheduling a personal meeting are welcome to contact Mr. Levi Perryman at levi@glomednet.com or visit Booth number 4.
About AmSECT 63rd International Conference
The American Society of ExtraCorporeal Technology (AmSECT) International Conference is the premier global event for perfusion professionals, focusing on advancements in extracorporeal circulation, patient care, and perfusion education. The event will feature the latest medical technologies, research, and discussions shaping the future of perfusion.
About Inspira Technologies
Inspira Technologies is developing innovative respiratory support and diagnostics technologies. The Company's flagship INSPIRA ART500 system aims to revolutionize critical care by enabling patients to remain awake during treatment while stabilizing oxygen levels without mechanical ventilation. The FDA-cleared INSPIRA ART100 system has received regulatory approvals for Cardiopulmonary Bypass procedures in the
For more information, visit: https://inspira-technologies.com
Company Contact
Inspira Technologies – Media Relations
Email: info@inspirao2.com
Phone: +972-9-9664485
Capital Markets & Investor Contact
Arx | Capital Markets Advisors
North American Equities Desk
inspira@arxadvisory.com
View original content:https://www.prnewswire.com/news-releases/inspira-technologies-innovative-life-support-system-to-be-showcased-at-amsect-63rd-international-conference-2025-in-san-diego-302405781.html
SOURCE Inspira Technologies
FAQ
When did the INSPIRA ART100 system receive FDA clearance for cardiopulmonary bypass procedures?
Where and when will Inspira Technologies (IINN) showcase their ART100 system?
Which company is distributing the INSPIRA ART100 system at the AmSECT conference?
What is the primary application of IINN's INSPIRA ART100 system?
